WWW.CUREVCP.ORG
info@curevcp.org
229.410.9573

2021 ANNUAL REPORT

CURE VCP DISEASE, INC.

ABOUT RARE DISEASE

7,000

DISTINCT RARE DISEASES EXIST TODAY

1 in 10

AMERICANS

30 million

IN USA

400 million

GLOBALLY ARE AFFECTED BY RARE DISEASE

RARE DISEASES IMPACT MORE PEOPLE THAN CANCER & AIDS COMBINED

65%

OF RARE DISEASES ARE ASSOCIATED WITH A REDUCED LIFESPAN

95%

OF ALL RARE DISEASES DO NOT HAVE A SINGLE FDA APPROVED DRUG TREATMENT

Data courtesy of Global Genes

THANK YOU ALL PARTICIPANTS IN OUR STUDIES!

CEO LETTER

During our historic VCP Scientific Conference in September 2021, numerous presentations from pre-clinical researchers were presented on the functional understanding of VCP. During one of the last presentations, one of the researchers commented, "perhaps we shouldn't be talking about all the things that VCP does, but rather what VCP doesn't do?" Everyone laughed, but the comment smacked me in the face of how little is still understood about what the valosin-containing protein regulates and facilitates within our bodies and how to best address our disease gene mutation.

Lindsay Alfano, PI at Nationwide with Nathan Peck

As a patient myself, I understand the urgency for speed in research. Our goal at Cure VCP Disease remains to let the scientists do their work, and be available to encourage and provide resources to optimize their work. We hosted the VCP Scientific Conference for this exact reason, to encourage the sharing of knowledge about VCP and collaboration among the research community. We are driving collaborations between institutions and industry as well as pressing scientific studies faster.

Nowhere was that more evident than our groundbreaking VCP Natural History Study with Nationwide Children's Hospital in Columbus, Ohio. Once the contract was signed, in less than one month, we were up and running with patients enrolled and traveling to Columbus. We have already entered the sixth month measurement period for that study and though the study has another six months to go, we are already learning unique things about the progression of VCP disease.

Meeting for dinner with University of California, Irvine research team

We didn't stop there though! A big topic in the rare disease community is sensitivity of measures in clinical trials. We would hate to see a therapeutic work, but not be able to measure the effectiveness in a rapid enough timeframe. That is why we have partnered with Casimir, a company started by concerned parents of Duchenne Muscular Dystrophy patients. With their leadership, we have started a second study that will run in parallel with the Nationwide Study to learn even more about the progression of VCP disease as well as compare and contrast the measures' outcomes and observations between the two studies.

We were also excited that our successful work was recognized by the Chan Zuckerberg Institute's Rare As One Project. In November, it was announced that we would receive a funding grant of $600,000, over a 3-year period to support Cure VCP Disease in the advancement of an international, patient-led collaborative research network in VCP disease, We are excited for big things in 2022!

With Hope,

Nathan Peck

This annual report aims to share some of our significant accomplishments for Cure VCP Disease in 2021. During a continued global pandemic, we have had an active and productive year towards driving collaborative research, increasing patient identification, and providing educational opportunities for the VCP disease community.



ALS - amyotrophic lateral sclerosis
CMT - Charcot-Marie-Tooth disease
PD - Parkinson's disease

ABOUT VCP DISEASE

VCP (Valosin containing protein, p97 gene) disease is a rare genetic mutation affecting 500-2,000 patients globally. Also known as IBMPFD and MSP1, the disease is autosomal dominant (meaning that a patient has a 50% chance of passing to offspring), adult-onset and can affect any combination of a patient's muscular, nervous and skeletal systems. Symptoms usually present in a patient's late 30's to early 40's. The disease is fatal and no treatments exist for the muscular and nervous system diseases.

CURE VCP DISEASE MISSION (EST. 2018)

Cure VCP Disease, Inc. was formed in 2018 to cure diseases related to valosin-containing protein (VCP) associated multisystem proteinopathy (MSP), also known as IBMPFD (Inclusion Body Myopathy, Early Onset Paget's Disease of Bone and Frontotemporal Dementia). The disease can affect any combination of a patient's muscles, bones, and brain. The specific objectives of our organization are to:

- provide global education and awareness of VCP disease;
- develop and maintain a global patient registry of VCP disease patients;
- develop and maintain a fundraising vehicle;
- collaborate with other global organizations and groups;
- sponsor, fund, host and participate in events and activities that promote efforts to advance treatments and cures for VCP disease.

We are entirely volunteer-led and count on patients, care partners, family, friends, and the generous time of scientists and researchers to advance our mission.

Board of Directors

CEO
Nathan Peck
Americus, Georgia

Secretary
Amy Casey
Cedar Rapids, Iowa

Treasurer
Allison Peck
Americus, Georgia

Bryan Van Brunt, JD
Brandon, Florida

David Kaminsky, PhD
Havertown, Pennyslvania

Brandon Feldt
Escondido, California

Maureen McArthur Hart, PhD
Carlsbad, California

Kelly Gold
Sandy Springs, Georgia

Medical Advisory Board

Virginia Kimonis, MD, MRCP
University of California, Irvine, California



Ming Guo, MD, PhD
University of California, Los Angeles, Cailfornia

Chris Weihl, MD, PhD
Washington University, St. Louis, Missouri

Tahseen Mozaffar, MD
University of California, Irvine, California

Gerald Pfeffer, MD, PhD
University of Calgary, Calgary, Alberta Canada

WHY PARTICIPATE IN NATURAL HISTORY STUDIES?

> Having a way to measure the effectiveness of future drugs is essential for future drug development. Natural history studies facilitate better disease understanding and develop a pathway for a cure.

TYPES OF NATURAL HISTORY STUDIES

RETROSPECTIVE

Retrospective studies look backwards at patients' medical histories.

AllStripes

Patients' medical record collection

- Free to patients
- Free to researchers

PROSPECTIVE

Prospective studies aim to understand the progression of the disease and are normally conducted over a period of 12 to 36 months.

CoRDS Registry
Coordination of Rare Diseases at Sanford

Annual patient reported outcome measures

- Started in 2018
- Global
- Free to patients
- Free to researchers

Nationwide Children's
When your child needs a hospital, everything matters.

Muscular outcome measures

- Using validated measures
- 12-month study
- In-clinic & remote
- Global
- Free to patients

casimir

Muscular outcome measures

- 12-month study
- Remote only
- USA only
- Free to patients

AllStripes

ENROLLED VCP DISEASE PATIENTS

47

ELIGIBLE COUNTRIES

ABOUT ALLSTRIPES

AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data.

In 2021, AllStripes became a Public Benefit Corporation (PBC), with a stated purpose to drive forward research for the rare disease community and create technology to break down research silos. A PBC is a company that weighs social good in its business decision-making.

AllStripes Demographic Reports



To view posters, go to: https://www.curevcp.org/allstripes and scroll down to posters

NATIONWIDE CHILDREN'S HOSPITAL
NATURAL HISTORY STUDY - IN-CLINIC & REMOTE

PROJECT GOAL

To study diagnosed VCP patients and understand the type and rate of degradation over a 12-month period. Evaluate if conducting measures remotely shows any a statistical difference than by conducting measures in-clinic.



Poster presented at Global Genes Rare Drug Development Symposium and NORD Rare Diseases and Orphan Products Breakthrough Summit. To zoom poster, go to: https://bit.ly/2021naturalhistoryposter

OUTCOMES

- Cure VCP Disease is providing travel stipends to help participants with travel to Columbus, Ohio for the in-clinic study.
- We have now opened the study to remote only VCP patients to encourage higher participation.
- Results will be published within 12 months upon the conclusion of the study in July 2022.

FINANCIALS

TOTAL PROJECT COST FOR 35 PATIENTS

$165,000

FOR 12 MONTHS
(PROJECT STARTED IN MAR 2021)

CASIMIR HOME-BASED STUDY - VCP VIDEO ASSESSMENT

PROJECT GOAL

To determine whether a VCP Video Assessment (VVA) would detect noticeable patient change over a shorter period of time than other proposed outcomes. In other words: is there a concrete advantage to pursuing this approach for trial design? This data could also be valuable for other rare diseases.

PROJECT DESIGN

Cure VCP Disease has contracted with Casimir (https://casimirtrials.com/) to perform a novel study to assess disease progression over time using video assessments with up to 25 VCP patients. Patients will submit videos of how they do everyday activities, like taking off a shirt or standing up from a couch. The advantage to this approach is that patients can be assessed from the comfort of their own home, and these customized measures may be more sensitive to distinct changes than other performance measures commonly used in clinical trials. A certified rater will assess each video using a customized multiple point scorecard. The VVA will take place at four time points; baseline, week 1, month 6 and month 12. Because no travel is involved to participate, burden to the patient is minimal and our home-bound patients can be included in future clinical trials. This project started in October 2021.

ABOUT CASIMIR

Casimir is a Contract Research Organization that develops novel outcomes for decentralized and hybrid trials in order to better understand disease progression and treatment benefit. Their creative protocols were vital in the approval of EXONDYS51, the first FDA-approved treatment for Duchenne Muscular Dystrophy. Because Casimir scorecards are more granular than what's quantified in traditional outcome measure scorecards, there is a possibility that more granular patient changes could be missed. Casimir designs and runs rigorous decentralized and hybrid studies designed to address the needs of regulators, payers, and patients.

FINANCIALS

TOTAL PROJECT COST FOR 25 PATIENTS

$76,425

FOR 12 MONTHS (PROJECT STARTED IN OCT 2021)

The burden of VCP disease is severe, and there are no approved treatments for VCP disease. VCP disease is a slowly progressing disease with the typical patient losing the ability to walk 5-10 years after diagnosis. VCP disease may affect a person's muscles, nerves, bones, and brain, but the disease will present differently between patients. For these reasons, it is unknown if measured change could be detected in one year with existing validated measures for other diseases (such as ALS, inclusion body myositis, limb-girdle muscular dystrophy scales).

PROJECT GOAL

To establish a multidisciplinary care guidelines to educate the VCP clinical and patient communities for appropriate pharmacotherapies and supportive therapies. Benefits also include expediting time-to-accurate diagnosis as well as improving the quality of care for patients.



Development of a standard of care for patients with valosin-containing protein (VCP) associated multisystem proteinopathy (MSP)

Manisha Korb1, Allison Peck4, Lindsay N Allan05, Kenneth I Berger6, Meredith K. James7, Mupur Ghosh8, Elise Healor9, Claire Henchcliffe1, Shaida Khan10, Pradeep P A Mammen11, Sujata Patel12, Gerald Pfeffer13, Stuart H Rankin34, Bhaskar Roy15, Bill Seeley16, Andrew Swenson17, Tahseen Mozaffar1,3, Conrad Weihl18, 19, Virginia Kimonis2,3, on behalf of the VCP Standards of Care Working Group

allison@curevcp.org
www.curevcp.org
@Allison38600974
allison-peck-vcp

AIM 1: Establishing a multidisciplinary standard of care for appropriate pharmacotherapies and supportive therapies
AIM 2: Expediting time to accurate diagnosis
AIM 3: Identify gaps and future directions for clinical research

METHODS
1. Recruited a multidisciplinary team of 50 physicians and therapists
2. Domain teams reviewed literature, exchanged ideas, and prepared a domain consensus recommendation based on expert opinion and adjacent disease practices
3. A virtual consortium meeting was held on April 9, 2021
4. Meeting discussion points integrating into one manuscript with team member sign-off

PATIENT ADVOCACY ROLE
1. Provided patient perspective in project scope
2. Recruited expert clinicians to participate
3. Organized communications, facilitated discussions, and hosted meetings
4. Assisted in literature review
5. Reviewed and edited the manuscript concerning patient perspective and symptoms

RESULTS
- Each domain team created a 2-5 page consensus guideline
- One multidisciplinary manuscript has been submitted for publication

Successful collaboration between patient advocacy and researchers for standard of care addresses **unmet patient need** in **rare disease:**
1. Delays in diagnosis and prolonged time to treatment
2. Delays in recognizing involvement of other organ systems
3. Disparate care between clinics
4. Disease development in at risk, undiagnosed family members

OUR STANDARD OF CARE DEVELOPMENT CYCLE

Physician Survey
Patient Registry
Informal Reports
Patients and physicians identified unmet patient needs
Experts recruited to exchange current knowledge
Team Meetings
Literature Review
Expert Dialogue
Care recommendations created, modified, accepted, and published
Clinical Features
Diagnosis
Management
Surveillance
Research projects launched to address gaps and future directions
Natural History
Clinical Studies
Case Studies

REFERENCES
1. Korb ME, Kimonis VE. Mozaffar T. Multisystem proteinopathy: Where myopathy and motor neuron disease converge. Muscle Nerve 2021;63:442-454.
2. Al-Obeidi E, Al-Tahan S, Surampalli A, et al. Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin Genet. 2018;93:119-125.
3. Evangelista T, Weihl CC, Kimonis V, Lochmuller H, Consortium VCPrd. 215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13-15 November 2015, Naarmeerk, The Netherlands. Neuromuscul Disord 2016;26:535-547.
4. Taylor JP. Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology 2015;85:658-660.
5. Mehta SG, Khare M, Ramani R, et al. Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia. Clin Genet 2013;83:422-431.
6. Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. J Bone Miner Res 2019;34:579-604.

ABOUT VCP ASSOCIATED MSP

Rare, heterogeneous, autosomal dominant, genetic disorder affecting multiple organ systems including the muscular, skeletal, and central nervous system

PREVALENCE OF PHENOTYPES
- Inclusion Body Myopathy ~ 90%
- Paget's disease of Bone ~ 40%
- Frontotemporal dementia ~ 30%
- Respiratory dysfunction ~ 40-50%
- Amyotrophic lateral sclerosis ~10%
- Parkinson disease ~ 4%
- Alzheimer disease ~ 2%
- Spastic paraplegia ~ isolated
- Charcot Marie Tooth disease ~ isolated
- Cardiomyopathy ~ unknown
- Urinary and anal dysfunction ~ unknown

MULTIDISCIPLINARY DOMAIN TEAMS
- Genetic diagnosis
- Myopathy
- Frontotemporal dementia
- Paget's disease of bone
- ALS and CMT
- Parkinson's disease/ parkinsonism
- Cardiomyopathy
- Respiratory dysfunction
- Supportive therapies (including physical and occupational therapy, speech language pathology)
- Mental health
- Supplements and nutrition

Poster presented at NORD Rare Diseases and Orphan Products Breakthrough Summit. To zoom poster, go to: https://bit.ly/SOCVCPPoster

PARTICIPATING CLINICIANS	PARTICIPATING COUNTRIES	DOMAINS ADDRESSED	CLINICIANS VOLUNTEERED THEIR TIME
50+	7	10	

OUTCOMES

A manuscript has been submitted to a medical journal that will reach a global medical audience. Next steps include the development of a summary patient guide that patients can provide to their doctor to increase awareness of VCP disease, expedite diagnosis, and foster better understanding of the type of care VCP disease patients require.

The VCP Scientific Conference was an international virtual meeting held on September 9-10, 2021. This multidisciplinary and collaborative conference created a forum for experts and trainees to share scientific knowledge and discuss future research directions. Hosted by Cure VCP Disease, this conference was the first VCP focused scientific meeting since the European Neuromuscular Commission (ENMC) meeting in 2015.

OBJECTIVES:

- Share scientific findings
- Develop young investigators
- Discuss research strategies
- Identify gaps and barriers so that therapies may be developed for VCP patients

To view all conference videos, go to: https://bit.ly/2021vcpconferencevideos

REGISTERED PARTICIPANTS	POSTER PRESENTERS	COUNTRIES REPRESENTED	SPEAKERS
157	28	9	26

OUTCOMES

In early 2022, a summary of the VCP Scientific Conference will be published for global scientific review. This will increase awareness of VCP disease and grow engagement and involvement. Cure VCP Disease will restart monthly VCP Focus Group meetings with participants.

FINANCIAL SUMMARY

AMOUNT RAISED BY YEAR



2021 EXPENDITURES

Reporting as of December 21, 2021



2021 GRANTS RECEIVED

Chan Zuckerberg Initiative / Rare As One

$200K

YEAR 1 FOR CAPACITY BUILDING

EVERYLIFE FOUNDATION FOR RARE DISEASES

$5K

CONDUCTING COMMUNITY EDUCATION OF RARE DISEASE LEGISLATIVE EFFORTS

AllStripes

$5K

COMMUNITY BUILDING

Monumental News: Cure VCP Disease was one of 20 patient-driven rare disease organizations (out of 200) selected to join the Rare As One Network. The funding grant of $600,000, over a 3-year period, will support Cure VCP Disease in the advancement of an international, patient-led collaborative research network in VCP disease, strengthen organizational capacity, convene the community, and align patients and researchers towards shared priorities.

Read more at: https://chanzuckerberg.com/newsroom/czi-awards-13-million-to-patient-led-organizations-advancing-rare-disease-research/

ACCELERATING PROGRESS

TOGETHER WE CAN MAKE A DIFFERENCE

Accomplishments - 2021